Granted Patent B2

US 12,516,099 · App. 17/267,000 · Granted Jan 6, 2026

Inventors: Matthew Westoby (Seattle, WA); Adrian Wrangham Briggs (Seattle, WA); David G. Kugler (Seattle, WA); Lothar Germeroth (Munich, DE); Christian Stemberger (Munich, DE); Mateusz Pawel Poltorak (Munich, DE); Divya Varun (Seattle, WA); Keenan Bashour (Seattle, WA); Robert Guy Caspary (Seattle, WA); Calvin Chan (Seattle, WA)

Assignee: Juno Therapeutics, Inc.

C07K14/7051A61K40/11A61K40/31A61K40/4211A61K40/4215A61P35/00C07K14/70521C12N5/0636A61K2239/48A61K2300/00C07K2317/622C12N2501/2302C12N2501/2307C12N2501/2315C12N2510/00

Abstract

Claims (60)

1 . A method for producing a composition of engineered T cells, the method comprising:

(a) exposing an input composition comprising primary T cells with a stimulatory reagent under conditions to stimulate T cells, wherein the stimulatory reagent comprises (i) an anti-CD3 antibody or antigen-binding fragment thereof and (ii) an anti-CD28 antibody or an antigen-binding fragment thereof, each bound to a bead, thereby generating a stimulated population;

(b) introducing into T cells of the stimulated population a viral vector comprising a heterologous polynucleotide encoding a recombinant protein, thereby generating a population of transformed T cells;

(c) incubating the population of transformed T cells in a serum-free medium, thereby generating an incubated population of transformed T cells, wherein the serum-free medium comprises 50 IU/mL to 200 IU/mL recombinant IL-2, 50 IU/mL to 200 IU/mL recombinant IL-15, and 500 IU/mL to 1,000 IU/mL recombinant IL-7, and wherein the heterologous polynucleotide becomes integrated into the genome of T cells of the incubated population;

(d) harvesting cells of the incubated population of transformed T cells, wherein the harvesting is carried out at a time between 48 and 120 hours, inclusive, after the exposing to the stimulatory reagent is initiated; and

(e) formulating the harvested cells in a composition for cryopreservation, wherein the formulated composition is suitable for use as a cell therapy for administration to a subject.

2 . The method of claim 1 , wherein the incubating is carried out for up to 96 hours.

3 . The method of claim 1 , wherein the incubating is carried out for between 60 hours to 120 hours.

4 . The method of claim 1 , wherein the incubating is carried out under static conditions.

5 . The method of claim 1 , wherein one or both of the exposing in (a) and the introducing in (b) is carried out in the presence of one or more recombinant cytokines, wherein the one or more recombinant cytokines comprise recombinant IL-2, recombinant IL-7, and recombinant IL-15.

6 . The method of claim 5 , wherein one or both of the exposing in (a) and the introducing in (b) is carried out in the presence of recombinant IL-2, recombinant IL-7 and recombinant IL-15.

7 . The method of claim 1 , wherein one or both of the exposing in (a) and the introducing in (b) is carried out in a serum-free medium.

8 . The method of claim 7 , wherein the serum-free medium in which one or both of the exposing in (a) and the introducing in (b) is carried out comprises recombinant IL-2, recombinant IL-7, recombinant IL-15, or any combination thereof.

9 . The method of claim 7 , wherein the serum-free medium in which one or both of the exposing in (a) and the introducing in (b) is carried out comprises recombinant IL-2, recombinant IL-7 and recombinant IL-15.

10 . The method of claim 9 , wherein the serum-free medium in which one or both of the exposing in (a) and the introducing in (b) is carried out comprises

(a) 50 IU/mL to 200 IU/mL recombinant IL-2,

(b) 500 IU/mL to 1000 IU/mL recombinant IL-7, and

(c) 50 IU/mL to 200 IU/mL recombinant IL-15.

11 . The method of claim 1 , wherein the input composition comprises at least about 300×10 6 viable primary T cells.

12 . The method of claim 11 , wherein the incubating is carried out for up to 96 hours.

13 . The method of claim 11 , wherein the incubating is carried out for between 60 hours to 120 hours.

14 . The method of claim 1 , wherein at least about 80% of the cells in the input composition are CD3+ T cells or are CD4+ T cells and CD8+ T cells.

15 . The method of claim 1 , wherein the input composition comprises a ratio of between 1.5:1 and 2.0:1 CD4+ to CD8+ T cells.

16 . The method of claim 1 , wherein the input composition comprises a ratio of about 1:1 CD4+ to CD8+ T cells.

17 . The method of claim 1 , wherein the method comprises prior to the exposing to the stimulatory reagent, enriching CD3+ T cells or CD4+ T cells and CD8+ T cells from a biological sample to produce the input composition and wherein the biological sample:

comprises primary T cells obtained from a subject;

comprises a whole blood sample, a buffy coat sample, a peripheral blood mononuclear cells (PBMC) sample, an unfractionated T cell sample, a lymphocyte sample, a white blood cell sample, an apheresis product, or a leukapheresis product; or

is an apheresis or leukapheresis product that has been previously cryofrozen prior to the enriching.

18 . The method of claim 1 , wherein the incubated population of transformed T cells is harvested as an output composition in one or more containers, wherein the output composition comprises at least about 5×10 6 total cells.

19 . The method of claim 1 , wherein the introducing is carried out in the presence of a transduction adjuvant.

20 . The method of claim 1 , wherein the recombinant protein comprises a TCR or antigen-binding fragment thereof.

21 . The method of claim 1 , wherein the recombinant protein is a chimeric antigen receptor (CAR).

22 . The method of claim 1 , comprising during or subsequent to the incubation adding an agent to reduce the binding between the stimulatory reagent and the T cells.

23 . The method of claim 1 , wherein the bead is a magnetic bead particle.

24 . The method of claim 23 , comprising during or subsequent to the incubation adding an agent to reduce the binding between the stimulatory reagent and the T cells.

25 . The method of claim 1 , wherein:

the stimulatory reagent comprises a magnetic bead bound to the anti-CD3 antibody or antigen-binding fragment thereof and the anti-CD28 antibody or antigen-binding fragment thereof;

the exposing and the introducing are carried out in the presence of serum free medium that includes recombinant IL-2, IL-7, and IL-15;

the incubating is carried out for between 24 hours and 96 hours; and

the harvesting is carried out at a time between 72 and 120 hours, inclusive, after the exposing to the stimulatory reagent is initiated.

26 . The method of claim 1 , the method further comprising adding a substance to the cells either subsequent to or during at least a portion of the incubating, wherein the substance terminates or lessens stimulation of the T cells by the stimulatory reagent.

27 . The method of claim 1 , wherein the serum-free medium comprises 0.5 mM to 5 mM of a dipeptide form of L-glutamine and 0.5 mM to 5 mM L-glutamine.

28 . A method for producing a composition comprising engineered T cells, the method comprising:

(a) stimulating a cell composition comprising CD4+ and CD8+ T cells obtained from a biological sample from a human subject, by exposing the cell composition to an anti-CD3 antibody or an antigen-binding fragment thereof and an anti-CD28 antibody or an antigen-binding fragment thereof, each bound to a bead, in a first serum-free medium, wherein the first serum-free medium comprises: (1) recombinant interleukin-2 (IL-2) at a concentration of 50 IU/mL to 200 IU/mL, (2) recombinant IL-7 at a concentration of 500 IU/mL to 1000 IU/mL; (3) recombinant IL-15 at a concentration of 50 IU/mL to 200 IU/mL, (4) a dipeptide form of L-glutamine at a concentration of 0.5 mM to 5 mM, and (5) L-glutamine at a concentration of 0.5 mM to 5 mM,

thereby producing a population of stimulated T cells;

(b) introducing a lentiviral vector into the T cells of the population of stimulated T cells and incubating the T cells, wherein:

(i) the introducing and incubating is in a second serum-free medium that comprises: (1) recombinant IL-2 at a concentration of 50 IU/mL to 200 IU/mL, (2) recombinant IL-7 at a concentration of 500 IU/mL to 1000 IU/mL; (3) recombinant IL-15 at a concentration of 50 IU/mL to 200 IU/mL, (4) a dipeptide form of L-glutamine at a concentration of 0.5 mM to 5 mM, and (5) L-glutamine at a concentration of 0.5 mM to 5 mM,

(ii) the lentiviral vector comprises a heterologous polynucleotide encoding a chimeric antigen receptor (CAR), and

(iii) the heterologous polynucleotide becomes integrated into the genome of T cells of the population;

(c) harvesting the T cells from step (b) between 48 hours and 120 hours, inclusive, after initiation of the stimulation in step (a); and

(d) formulating the harvested cells in a composition for cryopreservation, wherein the formulated composition is suitable for use as a cell therapy for administration to a subject.

29 . The method of claim 28 , wherein the first serum-free medium and the second serum-free medium each comprise:

(a) recombinant IL-2 at a concentration of 100 IU/mL to 200 IU/mL;

(b) recombinant IL-7 at a concentration of 500 IU/mL to 750 IU/mL; and

(c) recombinant IL-15 at a concentration of 100 IU/mL to 200 IU/mL.

30 . The method of claim 28 , wherein the total duration of the incubation is between 24 hours and 72 hours, inclusive.

31 . The method of claim 28 , wherein the harvesting is carried out at a time between 72 and 120 hours, inclusive, after the exposing to the stimulatory reagent is initiated.

32 . The method of claim 28 , wherein the biological sample is an apheresis product or a leukapheresis product.

33 . The method of claim 28 , wherein the cell composition comprising CD4+ and CD8+ T cells comprises at least about 300×10 6 viable primary T cells.

34 . The method of claim 28 , wherein at least about 80% of the cells in the cell composition comprising CD4+ and CD8+ T cells are CD4+ T cells or CD8+ T cells.

Assignments (3)

Continuity (6)

References Cited (400)